Study Reveals High Healthcare Costs for Hereditary Hemorrhagic Telangiectasia Patients in the US

Slipstream, a technology partner in the Pharmaceutical and Biopharmaceutical industry, co-authored a study on Hereditary Hemorrhagic Telangiectasia (HHT) published in the American Journal of Hematology. The study, the largest of its kind with over 24,000 HHT patients, revealed that annual direct medical costs for HHT in the US exceeded $450 million. The study highlighted the burden on patients and the healthcare system, emphasizing the need for advocacy and drug development.

Key findings showed that per patient per year costs for HHT were comparable to other rare diseases, with bleeding being the main cost driver. Patients with anemia accounted for a significant portion of costs, with mean annual costs exceeding $27,000. Slipstream's CEO emphasized the importance of leveraging data and expertise to drive healthcare advancements.

This study underscores the unmet needs of HHT patients and the necessity for therapeutic development. It showcases the value of real-world evidence and databases like Komodo Health in rare disease research.

The full article can be accessed at the American Journal of Hematology: Link.

About Slipstream: Slipstream is a technology partner for the Life Sciences industry, offering end-to-end solutions to simplify challenges across the product lifecycle.

About Slipstream’s Digital CRO Practice: Slipstream's Digital CRO Practice uses real-world data and data science to accelerate drug development for rare diseases, aiding companies in achieving faster drug approvals at reduced costs.

Media Contact:
Isabella Canuso
Sr. Marketing Manager
Slipstream
email protected
(609)682-1080
www.slipstream-it.com

According to the source: The Manila Times.